CA2601101A1 - Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre - Google Patents
Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre Download PDFInfo
- Publication number
- CA2601101A1 CA2601101A1 CA002601101A CA2601101A CA2601101A1 CA 2601101 A1 CA2601101 A1 CA 2601101A1 CA 002601101 A CA002601101 A CA 002601101A CA 2601101 A CA2601101 A CA 2601101A CA 2601101 A1 CA2601101 A1 CA 2601101A1
- Authority
- CA
- Canada
- Prior art keywords
- leucine
- acetyl
- unilateral
- syndromes
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960000669 acetylleucine Drugs 0.000 title claims abstract description 32
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title claims description 4
- 208000012639 Balance disease Diseases 0.000 title description 2
- 230000001720 vestibular Effects 0.000 claims abstract description 35
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 18
- 230000006735 deficit Effects 0.000 claims abstract description 17
- 230000001154 acute effect Effects 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 208000012886 Vertigo Diseases 0.000 claims description 9
- 231100000889 vertigo Toxicity 0.000 claims description 9
- 210000000860 cochlear nerve Anatomy 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 8
- 230000007850 degeneration Effects 0.000 abstract 1
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000012528 membrane Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 210000002569 neuron Anatomy 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000006260 foam Substances 0.000 description 7
- 230000036982 action potential Effects 0.000 description 4
- 230000010355 oscillation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 3
- 230000001144 postural effect Effects 0.000 description 3
- 238000002611 posturography Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 2
- WXNXCEHXYPACJF-SSDOTTSWSA-N N-acetyl-D-leucine Chemical compound CC(C)C[C@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-SSDOTTSWSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002310 reflectometry Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 208000001111 Bilateral Vestibulopathy Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010021089 Hyporeflexia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- -1 lyocs Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 230000003565 oculomotor Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003949 semicircular duct Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 201000000200 vestibular neuronitis Diseases 0.000 description 1
- 210000004440 vestibular nuclei Anatomy 0.000 description 1
- 210000001213 vestibule labyrinth Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0502696 | 2005-03-18 | ||
| FR0502696A FR2883180B1 (fr) | 2005-03-18 | 2005-03-18 | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| PCT/EP2006/060841 WO2006097527A1 (fr) | 2005-03-18 | 2006-03-17 | Utilisation de l'acétyl-leucine pour la préparation d'un médicament destiné au traitement de troubles de l'équilibre |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2601101A1 true CA2601101A1 (fr) | 2006-09-21 |
Family
ID=35134794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002601101A Abandoned CA2601101A1 (fr) | 2005-03-18 | 2006-03-17 | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080108702A1 (https=) |
| EP (1) | EP1865943A1 (https=) |
| JP (2) | JP2008533102A (https=) |
| CA (1) | CA2601101A1 (https=) |
| FR (1) | FR2883180B1 (https=) |
| WO (1) | WO2006097527A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| DK3359146T3 (en) * | 2016-08-11 | 2019-04-08 | Intrabio Ltd | PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3455638B2 (ja) * | 1996-02-23 | 2003-10-14 | 株式会社モリタ製作所 | 平衡機能検査装置 |
| FR2749512B1 (fr) * | 1996-06-10 | 1999-08-13 | Pf Medicament | Utilisation de l'acetyl dl leucine pour le traitement des tremblements |
| ID29095A (id) * | 1998-10-02 | 2001-07-26 | Novartis Ag Cs | Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan |
| WO2004096256A1 (en) * | 2001-01-23 | 2004-11-11 | The United States Of America, As Represented By The Secretary Of The Navy | Methods for preventing and treating loss of balance function due to oxidative stress |
-
2005
- 2005-03-18 FR FR0502696A patent/FR2883180B1/fr not_active Expired - Lifetime
-
2006
- 2006-03-17 CA CA002601101A patent/CA2601101A1/fr not_active Abandoned
- 2006-03-17 WO PCT/EP2006/060841 patent/WO2006097527A1/fr not_active Ceased
- 2006-03-17 US US11/886,419 patent/US20080108702A1/en not_active Abandoned
- 2006-03-17 JP JP2008501329A patent/JP2008533102A/ja active Pending
- 2006-03-17 EP EP06725137A patent/EP1865943A1/fr not_active Withdrawn
-
2013
- 2013-04-09 JP JP2013081360A patent/JP2013173759A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008533102A (ja) | 2008-08-21 |
| EP1865943A1 (fr) | 2007-12-19 |
| FR2883180B1 (fr) | 2007-05-25 |
| WO2006097527A1 (fr) | 2006-09-21 |
| FR2883180A1 (fr) | 2006-09-22 |
| JP2013173759A (ja) | 2013-09-05 |
| US20080108702A1 (en) | 2008-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1212060B1 (fr) | Utilisation de la nicotine ou de ses derives et de l-dopa dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson | |
| US20240024271A1 (en) | Methods and Compositions for Preventing and Treating Auditory Dysfunctions | |
| US11648261B2 (en) | Method of treating, reducing, or alleviating a medical condition in a patient | |
| Shakya et al. | Palatal mucosa as a route for systemic drug delivery: A review | |
| KR101429735B1 (ko) | 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 ｎｍｄａ 수용체 길항제의 용도 | |
| JPH08509202A (ja) | リポソーム、それを調製する方法及び薬調製におけるその用途 | |
| WO2005074535A2 (en) | Cholinesterase inhibitors for spinal cord disorders | |
| US8053424B2 (en) | Composition and method of treating hearing loss | |
| JP2018508479A (ja) | 虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用 | |
| ES2341789T3 (es) | Composiciones oftalmicas y metodos de uso de las mismas. | |
| CA2601101A1 (fr) | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre | |
| US10188695B2 (en) | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders | |
| AU2016223995B2 (en) | Extract of Taiwanese propolis for treating ocular diseases | |
| Hughes | Treatment of herpes simplex keratitis: a review | |
| Pauly et al. | Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFNγ and toxicological profiles | |
| EP0188538A1 (en) | TRANSDERMAL ADMINISTRATION OF AZATIDINE. | |
| JP2019519480A (ja) | パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用 | |
| FR2644060A1 (fr) | Medicament, notamment pour le traitement de maladies a virus du type herpes cutane, oculaire et genital | |
| EP2253316B1 (en) | Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits | |
| Vadakedath et al. | Pharmacology and pharmacotherapeutics: finding new avenues of research | |
| US20010051652A1 (en) | Method of treating paralysis of the extremities caused by cerebral infarction | |
| US8618167B2 (en) | Methods of attenuating cognitive deficits with sulfonyl fluorides | |
| KR101189261B1 (ko) | 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 nmda 수용체 길항제의 용도 | |
| AU2016223994A1 (en) | Compounds for treating ocular diseases | |
| Yamada | The Effect of Topical IL-1 Receptor Antagonist in the Cornea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20150102 |